Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB1211 capsule versus tablet food-effect pharmacokinetics crossover study in healthy volunteers
NL-OMON59571Phase 1Completed
- Sponsor
- Galecto, Inc.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selvigaltin, sponsored by Galecto, Inc. Primary endpoints: AUC0-last, AUC0-inf and 6 more. Started Dec 2022; status: completed.
02
Drugs
selvigaltin
Beyond the preview
Go deeper on NL-OMON59571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59571.